Gland Pharma bags USFDA nod for breast cancer treatment injection Eribulin Mesylate
"The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner," Gland Pharma stated.
Hyderabad: Gland Pharma Limited, a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).
Eribulin Mesylate Injection is used for the treatment of breast cancer that has spread to other parts of the body.
"The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner," Gland Pharma stated.
The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.
The Company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies Private Limited.
Read also: Gland Pharma bags tentative USFDA nod for Angiotensin II Injection for low BP treatment
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd